Research programme: glucose metabolism disorder therapeutics - Adocia

Drug Profile

Research programme: glucose metabolism disorder therapeutics - Adocia

Alternative Names: BC GlaD; BC GlaLira; BioChaperone glargine dulaglutide; BioChaperone Glargine GLP-1; BioChaperone glargine liraglutide

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 19 Jul 2017 Adocia plans a clinical trial for Diabetes mellitus in 2017
  • 20 Sep 2016 Preclinical trials in Diabetes mellitus in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top